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Abstract 
Aims/hypothesis The association between Sodium-glucose cotransporter 2 (SGLT2) 
inhibitors and risk of cancer in patients with type 2 diabetes remains uncertain. This 
study aimed to evaluate the cancer risk associated with SGLT2 inhibitors.  
Methods We systematically searched PubMed, EMBASE, Cochrane Central Register of 
Controlled Trials, and ClinicalTrials.gov from inception to February 15, 2017 to identify 
eligible randomized controlled trials (RCTs) that report cancer events in type 2 diabetes 
patients treated with SGLT2 inhibitors for at least 24 weeks. We performed pairwise and 
network meta-analyses as well as a cumulative meta-analysis to calculate their odds 
ratios (ORs) and 95% confidence intervals (CIs).  
Results In total, 580 cancer cases among 34,569 patients were identified from 46 
independent RCTs with a mean trial duration of 61 weeks. When compared to 
comparators (placebo or other active anti-diabetic treatments), SGLT2 inhibitors were 
not significantly associated with increased risk of overall cancer (OR 1.14 [95% CI 0.96, 
1.36]). For pre-specified cancer types, SGLT2 inhibitors might increase risk of bladder 
cancer (OR 3.87 [95% CI 1.48, 10.08]), especially for empagliflozin (OR 4.49 [95% CI 
1.21, 16.73]). Interestingly, canagliflozin might be protective against gastrointestinal 
cancers (OR 0.15 [95% CI 0.04, 0.60]).  
Conclusions/interpretation Current evidence from short term RCTs did not indicate a 
significantly increased risk of overall cancer among type 2 diabetes patients using 
SGLT2 inhibitors. Given the short term trial durations and uncertainty of evidence, future 
long-term prospective studies and post-marketing surveillance studies are warranted.  
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Introduction 
Growing evidence suggests that patients with type 2 diabetes are at elevated risk for 
cancer [1, 2]. Though the clear mechanisms remain unknown, several carcinogenic 
processes involving the pathophysiology of type 2 diabetes may explain increased 
cancer risk with type 2 diabetes. Certain diabetes risk factors (e.g., obesity) play a 
significant role in increasing cancer risk [3]. Furthermore, several antidiabetic drugs have 
the potential to affect cancer risk [1]. For example, metformin therapy has been shown to 
decrease the risk of cancer, while other such drugs may increase the risk of specific 
cancers [4]. Recently, concern was raised about a potential link between 
thiazolidinedione (e.g., pioglitazone) and bladder cancer [5]. However, no clear 
conclusions have been drawn regarding a causal relationship [6].  
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a novel class of oral antidiabetic 
drugs for treating type 2 diabetes [7]. They decrease plasma glucose levels by 
selectively inhibiting renal glucose reabsorption and increasing urinary glucose excretion 
[8, 9]. In addition to their hypoglycemic effects, SGLT2 inhibitors also offer additional 
benefits for weight loss and reduction of blood pressure [10]. In clinical practice, SGLT2 
inhibitors are recommended combination with metformin and/or other agents as 
second-line or third-line choices after not achieving the target level of glycemic control of 
one or more other agents [11]. 
In 2011, a regulatory submission presented to the U.S. Food and Drug Association (FDA) 
raised concerns regarding the risk of bladder cancer and breast cancer associated with 
dapagliflozin [12]. An imbalance between dapagliflozin and comparators in the risk of 
bladder cancer and breast cancer was observed in the 2011 report [12]. However, a 
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recent pooled analysis of 21 clinical trials suggested that the increased risk of bladder 
and breast cancers might be an absence of detailed diagnosis prior to randomization 
rather than a causal relationship[13]. No elevated risk of bladder or breast cancer was 
reported for other SGLT2 inhibitors in humans[14] , although it was indicated that they 
might induce tumors in rats [15] and male mice [16]. Given conflicting results regarding 
possible associations with rare cancers, individual trials were not powerful enough to 
clarify the cancer risk associated with the use of SGLT2 inhibitors. We therefore 
performed a pairwise meta-analysis of all available head to head randomized controlled 
trials (RCTs) data to test the hypothesis that SGLT2 inhibitors affect cancer risk by 
comparing SGLT2 inhibitors with placebo in patients with type 2 diabetes. We also 
carried out a network meta-analysis to evaluate the comparative effects of SGLT2 
inhibitors on cancer risk using combination of direct and indirect evidence based on a 
common comparator (e.g., placebo).  
Methods 
This network meta-analysis was performed according to the PRISMA extension 
statement for reporting of systematic reviews incorporating network meta-analyses of 
health care interventions [17] and was registered with PROSPERO 
(number CRD42016045707). 
Search strategy and study selection We comprehensively searched PubMed, 
Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception 
to February 15, 2017 to identify eligible RCTs using the following search terms: random*, 
RCTs, sodium–glucose cotransporter, SGLT2, SGLT-2, and the names of 10 individual 
SGLT2 inhibitors. No restrictions were applied in terms of language, date, or publication. 
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In addition, we also identified other published and unpublished trials by manually 
searching the references of included trials and relevant meta-analyses as well as 
ClinicalTrials.gov. Detailed information about our search strategy is presented on ESM 
Table 1. Furthermore, we reviewed the submission documents provided to the U.S. FDA 
or European Medicines Agency (EMA) for more data. Two reviewers independently 
selected the studies according to the following inclusion criteria: 1) RCTs that compared 
SGLT2 inhibitors with placebo or other active antidiabetic treatments in adult patients 
with type 2 diabetes; 2) trial durations ≥24 weeks; and 3) studies reporting any cancer as 
an outcome. Our primary outcome measure was risk of overall cancer and the secondary 
outcomes included risk of pre-specified cancer types including skin, breast, respiratory, 
gastrointestinal, bladder, prostate, and renal (ESM Table 2). Any cancer event was 
reported by investigators as a serious adverse event identified in the database using 
pre-specified lists from the Medical Dictionary for Regulatory Activities (MedDRA). 
Conference abstracts were excluded due to lack of detailed information on the trials’ 
characteristics, definition of outcome, and trial quality. 
Data extraction and quality assessment Two reviewers (HT and WS) independently 
extracted the following data: first author, publication year, study characteristics (country 
of origin, funding, and follow-up), characteristics of patients (inclusion criteria, 
background treatments, mean age, proportion of men, duration of type 2 diabetes, 
baseline HbA1c%, and body mass index [BMI]), interventions (type and dose of SGLT2 
inhibitors), comparators, and the incidence of cancer.  
If multiple reports from the same population were retrieved, only the most complete 
and/or most recently reported data were used. If cancer events were not reported in the 
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manuscripts, data from regulatory submissions or the “Serious Adverse Events” section 
on the ClinicalTrials.gov were extracted. In addition, if pre-specified cancer outcomes 
were not reported on ClinicalTrials.gov, the incidence of the events was assumed to be 
zero. If two different comparison groups of non-overlapping patients (i.e., A vs. B and C 
vs. D) were included in the same report, each comparison was considered separately. If 
three arms (i.e., A vs. B vs. A+B) were evaluated in the RCTs, only two arms (A vs. B) 
were included.  
The Cochrane risk of bias tool was used to assess the quality of RCTs based on the 
following domains: random sequence generation (selection bias), allocation 
concealment (selection bias), blinding (performance bias and detection bias), incomplete 
outcome data (attrition bias), and selective reporting (reporting bias) [18]. Two reviewers 
(HT and WS) independently reviewed and judged each domain as low risk of bias, high 
risk of bias, or unclear risk of bias.  
Statistical analysis Both pairwise and network meta-analyses were performed to 
calculate their odds ratios (ORs) and 95% confidence intervals (CIs) of overall cancer or 
pre-specified types of cancer. All meta-analyses were performed with STATA (Version 14; 
Stata Corp., College Station, TX). 
For pairwise meta-analysis, Peto’s method was used to calculate the ORs for direct 
comparisons between therapeutic regimens due to low event rate [19]. An I² statistic was 
used to evaluate the presence of between-study heterogeneity, with I2 of <25%, ≥25 and 
<75% , and ≥75% indicating low, medium, and high heterogeneity, respectively [20]. The 
source of heterogeneity was further explored in the following pre-specified subgroups: 1) 
type of SGLT2 inhibitors (canagliflozin vs. dapagliflozin vs. empagliflozin); 2) type of 
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control groups (placebo vs. other active treatment); 3) length of trial duration (< 52 vs. ≥ 
52 weeks); 4) mode of therapy (SGLT2 inhibitor monotherapy vs. SGLT2 inhibitor added 
on therapy); 5) race/ethnicity (White vs. Asian); 6) mean age (≥ 60 years vs. < 60 years); 
7) mean BMI (≥ 30 vs. < 30 kg/m2); and 8) mean percentage of male subjects (≥ 50% vs. 
< 50%). Additionally, a meta-regression was performed to explore whether the above 
variables influenced the size of intervention effects. A sensitivity analysis was carried out 
by comparing two statistical methods (Peto vs. Manthel-Haenszel method), comparing 
two effect measures (odds ratio vs. risk ratio), or excluding the largest trial (EMPA 
REG-OUTCOME Trial) [21]. In addition, a cumulative meta-analysis was performed to 
explore the evolution of the evidence with the accumulation of data over time. Finally, 
potential publication bias was assessed by Begg’s and Egger’s tests, as well as visual 
inspection of the funnel plots. 
For indirect and mixed comparisons, a network meta-analysis with a random-effects 
model using the “mvmeta” command and programmed STATA routines was used to 
compare different interventions [22, 23]. For zero-event RCT, a 0.5 zero-cell correction 
was applied before meta-analysis[24]. To rank the SGLT2 inhibitors for a specified 
outcome, we estimated the relative ranking probabilities of each treatment using the 
surface under the cumulative ranking curve (SUCRA) and mean ranks. For incidence of 
cancer, large SUCRA probability and lower mean rank indicate a safer intervention[25]. 
The heterogeneity variance (tau) estimated by a restricted maximum likelihood method 
was employed to investigate between-study heterogeneity in the network meta-analysis 
[26] . 
To check for the presence of inconsistency, a loop inconsistency–specific approach was 
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introduced to evaluate the difference between direct and indirect estimates for a specific 
comparison[27]. To check the assumption of consistency in the entire network, a 
design-by-treatment interaction model using the χ2 test was used [28]. In addition, a 
comparison-adjusted funnel plot was used to assess small study effects within a network 
of interventions [29]. 
Results 
Study selection and Study characteristics A total of 2,450 citations were retrieved 
through electronic search, and then 201 potentially eligible reports were identified by 
reviewing study titles and abstracts. After fully reviewing the potential trials and 
searching lists of references and ClinicalTrials.gov. Finally, 45 articles with 46 
independent RCTs were eligible and included in this meta-analysis [21, 30-73] (ESM 
Fig.1). Two articles provided two independent datasets for two different comparisons, 
respectively, which we considered separately [42, 58]. Because data from two trials were 
presented together on ClinicalTrials.gov, we included the combined data as one 
independent trial [70, 71]. 
The study characteristics are summarized in ESM Table 3. Totaling 34,569 patients from 
46 independent trials were randomly assigned to one of three SGLT2 inhibitors 
(canagliflozin, dapagliflozin, and empagliflozin) or comparators (placebo or other active 
anti-diabetic treatments). Sample sizes of individual trials were between 180 and 7,020 
participants, and the mean trial duration was 61 weeks (range: 24 -160 weeks).The 
spread of trial duration for each SGLT2 inhibitors is presented on ESM Fig. 2.  
The risk of bias for the 46 RCTs is summarized as follows (ESM Fig. 3): 36 RCTs 
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reported adequate random sequence generation; 33 RCTs reported adequate allocation 
concealment; masking conditions were high in 3 RCTs, of which 2 RCTs were open label 
in their extended periods and one RCT set one arm with open label; finally, all RCTs 
were judged as unclear for selective reporting because none included cancer events as 
outcomes of interest. All of the trials were funded by industrial companies.  
Pairwise meta-analysis Forty-six trials reported the incidence of overall cancer with a 
total of 580 events among 34,569 patients (a crude event rate of 1.68%). Cancer rates 
were 1.78% in the SGLT2 inhibitor treatment groups and 1.55% in the comparator 
groups. The results of overall and subgroup pairwise meta-analysis are presented in Fig. 
1. There was no significant difference between SGLT2 inhibitors and comparators in 
overall cancer risk (OR 1.14 [95% CI 0.96, 1.36]), with low statistical heterogeneity (I2 = 
19.2%) (ESM Fig. 4). The pre-specified subgroup analyses showed that SGLT2 
inhibitors were significantly associated with increased risk of overall cancer only in obese 
patients with mean BMI ≥30 kg/m2 (OR 1.23 [95% CI 1.02, 1.48]) (Fig.1). We found no 
significant difference between SGLT2 inhibitors and placebo (OR 1.17 [95% CI 0.96, 
1.41]) and between SGLT2 inhibitors and other active treatments (OR 1.03 [95% CI 0.67, 
1.57]). Our meta-regression analysis indicated that none of the pre-specified factors, 
significantly influenced the sizes of treatment effects (p all > 0.05). There was low 
heterogeneity among studies (I2 ranged from 0 to 36.1%). Our cumulative meta-analysis 
based on publication year showed that SGLT2 inhibitors were not significantly 
associated with increased risk of overall cancer (Fig. 2). 
In the sensitivity analysis, the results remained robust to different pairwise-meta analysis 
methods and the exclusion of the largest trial (EMPA-REG OUTCOME Trial) (OR 1.03 
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[95% CI 0.81, 1.33]) (ESM Table 4 and ESM Fig. 5). Moreover, our analysis yielded no 
evidence of substantial publication bias, based on the Egger’s test (p = 0.31), Begg’s test 
(p = 0.72), and a visual inspection of the funnel plot (ESM Fig. 6). 
When pre-specified types of cancer were analyzed, SGLT2 inhibitors were significantly 
associated with increased risk of bladder cancer (OR 3.87 [95% CI 1.48, 10.08]), 
particularly in the comparison of empagliflozin versus comparators (OR 4.49 [95% CI 
1.21, 16.73]). Canagliflozin was significantly associated with lower risk of gastrointestinal 
cancers than comparators (OR 0.15 [95% CI 0.04, 0.60]). No significant differences 
between SGLT2 inhibitors and comparators were observed in the risks of other 
pre-specified cancer types (Fig. 3). For bladder cancer risk, a further subgroup analysis 
indicated a significantly increased risk in the trials with durations ≥ 52 weeks (OR 4.80 
[95% CI 1.74, 13.29]), mean BMI ≥ 30 kg/m2 (OR 3.57 [95% CI 1.40, 15.48]), or mean 
age ≥ 60 years (OR 3.57 [95% CI 1.09, 11.66]) (ESM Fig.7). In addition, there was low to 
medium heterogeneity among studies (I2 ranged from 0 to 52.1%).  
Network meta-analysis The trial network plot and the results of network meta-analysis 
for overall cancer risk are presented in ESM Fig.8 and Fig. 4, respectively. Compared 
with placebo, none of canagliflozin (OR 0.74 [95% CI 0.35, 1.55]), dapagliflozin (OR 1.02 
[95% CI 0.68, 1.53]), and empagliflozin (OR 1.03 [95% CI 0.65, 1.64]) was significantly 
associated with increased risk of overall cancer; the incidence of overall cancer was 
similar among these three SGLT2 inhibitors. We generated hierarchies of treatment 
effects based on the SUCRA probabilities, canagliflozin was ranked the lowest risk for 
over cancer among these SGLT2 inhibitors (ESM Table 5). There was low 
between-study heterogeneity (tau = 0.25) (ESM Table 6), no inconsistency between 
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direct and indirect estimates (all 95% CIs across zero) (ESM Table 7), and no global 
inconsistency within any network (p = 0.83) (ESM Table 8). In addition, the 
comparison-adjusted funnel plot indicated the absence of small-study effects (ESM Fig. 
9).  
When different types of cancer were analyzed (ESM Figs 10 to 16), canaglifozin was 
significantly associated with decreased risk of gastrointestinal cancers as compared with 
placebo (OR 0.31 [95% CI 0.11, 0.88]), empagliflozin (OR 0.25 [95% CI 0.08, 0.75]), or 
other active treatments (OR 0.28 [95%CI 0.09, 0.88]), respectively (ESM Fig. 11), and 
canagliflozin was placed as the safest intervention among these interventions for its 
largest SUCRA probability and lowest mean rank (ESM Table 5). In contrast to the 
results from pairwise meta-analysis, empaglifozin was not significantly associated with 
increased risk of bladder cancer as compared with placebo (OR 0.52 [95% CI 0.14, 1.90]) 
(ESM Fig. 12). There was low between-study heterogeneity (tau ≈ 0) (ESM Table 6), no 
inconsistency between direct and indirect estimates (all 95% CIs across zero) (ESM 
Table 7), and no global inconsistency within any network (p > 0.05) (ESM Table 8) 
Discussion 
Our meta-analysis included 46 RCTs that reported 580 cases among 34,569 patients 
with type 2 diabetes. We found that SGLT2 inhibitors were not significantly associated 
with increased risk of overall cancer during the mean trial duration of 61 weeks. Our 
meta-regression analysis identify none of pre-specified factors significantly influenced 
the sizes of treatment effects. However, there was some evidence suggested that 
SGLT2 inhibitors might increase this risk in obese patients (BMI ≥ 30 kg/m2). For 
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pre-specified cancer types, SGLT2 inhibitors might significantly increase bladder cancer 
risk, particularly for empagliflozin. The increased risk was observed in the trials with 
duration ≥ 52 weeks and obese patients (BMI ≥ 30 kg/m2). Interestingly, there was 
suggestive evidence that canagliflozin was significantly associated with decreased risk 
of gastrointestinal cancers. However, given the short term RCTs clinical trials, estimates 
of cancer caused by longer exposure to SGLT2 inhibitors are not possible. Thus, our 
results should be interpreted with caution. 
Our meta-analysis of current available evidence from RCTs indicated no elevated risk of 
overall cancer associated with SGLT2 inhibitors. Our results were consistent with one 
previous meta-analysis of data from regulatory submissions and scientific reports, which 
also showed no effect on risk of cancer [74]. One pooled analysis of 21 phase-2b/3 
clinical trials showed that the overall incidence of malignancies was balanced between 
the dapagliflozin group and comparator groups [13]. Additionally, the overall incidence of 
bladder, breast, and renal cancers was not increased by canagliflozin relative to 
comparators in a pooled analysis of eight phase-3 clinical trials [14]. Furthermore, the 
results from pre-clinical studies found no increased hyperplasia or neoplasia in the 
urinary bladder mucosa, urogenital tract, or kidney in SGLT2 knockout mice compared 
with those with wild type [75]. However, our results included only 580 cases from 46 
short term RCTs with a mean trial duration of 61 weeks (range: 24 weeks to 160 weeks). 
Also, we observed a non-significant risk increase among patients using SGLT2 inhibitors 
with a lower border of CI of 0.96 (OR 1.17 [95% CI 0.96, 1.41]). We cannot completely 
rule out the possibilities of cancer risk. Our findings are needed to be confirmed by future 
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large trials including CANVAS (cannagliflozin; NCT01032629) and DECLARE-TIMI58 
(dapagliflozin; NCT01730534) as well as long term observational studies. 
Interestingly, our meta-analysis of direct and indirect evidence showed that canagliflozin 
was significantly associated with decreased risk of gastrointestinal cancers. SGLT1 was 
found to be overexpressed in many cancers [76], and SGLT2 is functionally expressed in 
pancreatic and prostate adenocarcinomas [77]. SGLT, especially SGLT1, has been 
demonstrated to play an important role in cancer cell survival by taking up glucose [77]. 
Canagliflozin is a potent SGLT2 inhibitor but possesses potent SGLT1 inhibitory activity 
[76]. SGLT1 is expressed mainly in the gastrointestinal tract, but is also expressed in 
kidney and heart, while SGLT2 is highly selectively expressed in kidney and less so in 
the gastrointestinal tract [78]. Therefore, it suggests that canagliflozin may protect 
against gastrointestinal cancers by suppressing the expression of SGLT1 and SGLT2 in 
the gastrointestinal tract. In human colon cancer cells not expressing UGT1A9, which 
encodes the enzyme for metabolizing SGLT2 inhibitors, dapagliflozin significantly 
reduced the number of colon cells [79]. However, our meta-analysis did not detect any 
decreased risk of gastrointestinal cancers with the use of dapagliflozin or empagliflozin. 
This might be explained by the fact that empagliflozin and dapagliflozin exhibited higher 
selectivity for SGLT2 versus SGLT1 than canagliflozin [76], or small number of 
gastrointestinal cancer cases included. Further prospective studies are needed to 
determine the potential effects of SGLT2 inhibitors on risk of gastrointestinal cancers. 
Risk of increased bladder and breast cancer remains a safety issue associated with 
SGLT2 inhibitors. Our pairwise meta-analysis showed that SGLT2 inhibitors (particularly 
empagliflozin) were significantly associated with bladder cancer, though this was not 
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confirmed in the network meta-analysis. Most bladder cases were identified from the 
EMPA-REG OUTCOME Trial (empagliflozin: 6 cases of bladder cancer, 2 cases of 
bladder transitional cell carcinoma, and one case of bladder cancer recurrent; placebo: 0 
cases) [21]. An increased risk of bladder cancer was observed in the patients taking  
empagliflozin as compared with placebo in this trial [21], which was consistent with the 
findings on dapagliflozin in the regulatory report submitted to the U.S. FDA [12]. However, 
our meta-analysis did not find that dapagliflozin significantly increase the risk of bladder 
cancer, nor was this risk affected by use of canagliflozin. One pooled analysis of eight 
phase-3 clinical trials based on regulatory submissions (canagliflozin: 5 cases; 
comparators: 4 cases) showed that the incidence of bladder cancer was no higher in the 
canagliflozin group than in other groups [14]. The mechanisms underlying the elevated 
risk of bladder cancer associated with SGLT2 inhibitors remain unclear. Diabetes and 
obesity are indeed risk factors for bladder cancer, and the glycosuria and urinary tract 
infection related to SGLT2 inhibitor use may be responsible for that increased risk [14]. 
We found a significantly increased risk of bladder cancer among the obese patients (BMI 
≥ 30 kg/m2) or the trials with duration ≥ 52 weeks. On the other hand, our meta-analysis 
did not detect a significantly increased risk of breast cancer with the use of SGLT2 
inhibitors as compared with comparators. However, the possibility of increased these 
risks cannot be excluded, as the short duration of RCTs is probably insufficient to 
address these questions. Future large long-term RCTs and real-world data are required 
to clarify the association between SGLT2 inhibitor and risk of pre-specified cancer types 
(especially for SGLT2 inhibitors and bladder cancer risk). 
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Several pre-specified risk factors (e.g., ethnicity, gender, BMI, and age) were further 
explored in our meta-regression analysis. However, none of the results were significant. 
In the subgroup analysis, we found that SGLT2 inhibitors as compared with comparators 
were significantly associated with increased risk of overall cancer or bladder cancer in 
obese patients (BMI ≥ 30 kg/m2) but not in normal weight/overweight subgroup. The 
disparate findings may be explained by imbalanced sample sizes. It should be noted that 
the significantly increased risk was largely driven by EMPA-REG OUTCOME Trial [21], 
which contributed over 50% of the weights to the overall results and even more weights 
to the subgroup results. Overweight and obesity are risk factors for several types of 
cancer (e.g., bladder cancer) [80, 81]. Future prospective studies are needed to clarify 
the subgroup findings.  
Compared with the null finding regarding overall cancer risk in one previously published 
meta-analysis [74], our meta-analysis not only showed a non-significantly increased risk 
of overall cancer associated with SGLT2 inhibitors, but also suggests some novel and 
important findings: (1) SGLT2 inhibitors in general might increase risk of overall cancer in 
obese patients; (2) SGLT2 inhibitors (especially empagliflozin) might increase risk of 
bladder cancer; and (3) canagliflozin might have a protective effect against 
gastrointestinal cancers. Furthermore, our meta-analysis has several advantages: (1) 
our research question was specific regarding incidence of cancer, including both overall 
cancer and pre-specific cancer types; (2) this is the first network meta-analysis to 
comprehensively assess the comparative effects of SGLT2 inhibitors on cancer risk; (3) 
RCTs from electronic databases were systematically searched, and additional data from 
Clinicaltrials.gov were also included; and (4) multiple subgroup analyses, 
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meta-regression, and sensitivity analysis were performed to test the robustness of our 
findings.  
However, several limitations of our study merit consideration. First, a large number of 
potentially eligible trials were not included in the meta-analysis due to lack of data on 
incidence of cancer, though additional data on ClinicalTrials.gov and regulatory reports 
submitted to U.S. FDA and EMA were searched and retrieved to minimize publication 
bias and outcome-reporting bias. The data of canagliflozin and empagliflozin from 
regulatory submissions were not included due to only total number of cases reported 
from several trials, which made it difficult to assign these outcomes to each trial. 
However, these results were compared in the discussion. Second, The exposure or 
follow-up time in most trials (mean trial durations: 61 weeks; range: 24 to 160 weeks) 
were not long enough to detect incidence of cancer given the long latency period of 
cancer. The evidence at this point is far from convincing, and therefore, it is likely that the 
observed associations may be caused by chance and may reflect their effects on late 
stage of carcinogenesis. Third, the quality of our evidence were relatively low due to 
indirect comparisons, inadequate power, and wide CIs according to the GRADE system 
[82]. Also, we cannot rule out any heterogeneity and inconsistency due to sparse cancer 
events among the trials. It is premature to apply our results from the analyses to clinical 
practice and guideline development. Fourth, background treatments and patient 
characteristics varied among the RCTs and might contribute to heterogeneity, although 
multiple subgroup analyses were performed to minimize clinical heterogeneity. Finally, 
the risk of cancer associated with other novel SGLT2 inhibitors remains uncertain due to 
lack of RCT data. 
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In conclusion, current evidence from RCTs does not show a significant association 
between SGLT2 inhibitors and an increased risk of overall cancer. There was some 
evidence suggested that SGLT2 inhibitors (especially empagliflozin) might increase the 
risk of bladder cancer, while canagliflozin might offer a protective effect against 
gastrointestinal cancers. However, given the relatively short term clinical trials, the long 
term effects of SGLT2 inhibitors on cancer remains uncertain. Future long-term 
prospective studies and post-marketing surveillance studies are warranted. 
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Figure Legends: 
Fig. 1 Pairwise meta-analysis of the effects of SGLT2 inhibitors on risk of overall cancer. 
n/N, number of cases/number of patients; metareg, meta-regression analysis 
Fig. 2 Cumulative meta-analysis of the effects of SGLT2 inhibitors on risk of overall 
cancer.  
Fig. 3 Pairwise meta-analysis of the effects of SGLT2 inhibitors on risk of pre-specified 
cancer types. n/N, number of cases/number of patients. 
Fig. 4 Network meta-analysis of the effects of SGLT2 inhibitors on risk of overall cancer.  
Common heterogeneity between studies were low (tau=0.25). CANA, canagliflozin; 
DAPA, dapagliflozin; EMPA, empagliflozin; PLA, placebo; ACT, other active treatments; 
CI, confidence interval.  
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